| Factor Information | |
|---|---|
| Data ID | 2526 |
| Factor | correlation between BMI and higher AIT risk |
| Description | N/A |
| Biomarker | NA |
| Classification | Z (combined factor - combined factor) |
| Association | |
|---|---|
| Application | risk assessment and prognosis |
| Objective | Amiodarone-induced thyrotoxicosis (AIT) is a recognized complication of amiodarone treatment with limited management options. Its predisposing factors are incompletely defined yet a higher prevalence was reported in adults with congenital heart disease (CHD). Therefore we sought to determine the incidence and risk factors for AIT in adults with CHD. |
| p Value | <0.001 |
| OR | 6.1 |
| Conclusion | BMI<21 at initiation of amiodarone therapy and presence of goiter are strong predictors of AIT in this population. Its incidence is time dependent. These predictors can be used clinically in assessing overall impact of amiodarone therapy in congenital heart disease patients. |
| Risk Factor | risk factor |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 22386642 |
| Year | 2013 |
| Title | Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease—A cohort study |
| Sample | ||
|---|---|---|
| Population | adults | |
| Source | patients' data | |
| Region | Rochester, America | |
| Method | univariate analysis | |
| Race | American | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | group with AIT (amiodarone-induced thyrotoxicosis)(Treatment) | group without AIT(Control) |
| Number | 23 | 146 |
| Age | 3.51(2.7-5.2) | 2.96(3.05-4.12) |
| Gender (Male: Female) | 13:10:00.000 | 76:93 |
| Marker Level | N/A | N/A |
